|
1
|
Nikolaou V, Sibaud V, Fattore D, Sollena
P, Ortiz-Brugués A, Giacchero D, Romano MC, Riganti J, Lallas K,
Peris K, et al: Immune checkpoint-mediated psoriasis: A multicenter
European study of 115 patients from the European network for
cutaneous adverse event to oncologic drugs (ENCADO) group. J Am
Acad Dermatol. 84:1310–1320. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Monsour EP, Pothen J and Balaraman R: A
novel approach to the treatment of pembrolizumab-induced psoriasis
exacerbation: A case report. Cureus. 11:e58242019.PubMed/NCBI
|
|
3
|
Johnson D, Patel AB, Uemura MI, Trinh VA,
Jackson N, Zobniw CM, Tetzlaff MT, Hwu P, Curry JL and Diab A:
IL17A blockade successfully treated psoriasiform dermatologic
toxicity from immunotherapy. Cancer Immunol Res. 7:860–865. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
European Medicines Agency, . https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_it.pdf
|
|
5
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen CH, Yu HS and Yu S: Cutaneous adverse
events associated with immune checkpoint inhibitors: A review
article. Curr Oncol. 29:2871–2886. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cutroneo P, Ingrasciotta Y, Isgrò V, Rullo
EV, Berretta M, Fiorica F, Trifirò G and Guarneri C: Psoriasis and
psoriasiform reactions secondary to immune checkpoint inhibitors.
Dermatol Ther. 34:e148302021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Belum VR, Benhuri B, Postow MA, Hellmann
MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD
and Lacouture ME: Characterisation and management of dermatologic
adverse events to agents targeting the PD-1 receptor. Eur J Cancer.
60:12–25. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scarfì F, Lacava R, Patrizi A, Tartari F,
Ravaioli GM, Veronesi G, Lambertini M and Dika E: Follicular
psoriasis induced by pembrolizumab in a patient with advanced
non-small-cell lung cancer. Int J Dermatol. 58:e151–e152. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haanen JBAG, Carbonnel F, Robert C, Kerr
KM, Peters S, Larkin J and Jordan K; ESMO Guidelines Committee, :
Management of toxicities from immunotherapy: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28
(Suppl 4):iv119–iv142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Voudouri D, Nikolaou V, Laschos K,
Charpidou A, Soupos N, Triantafyllopoulou I, Panoutsopoulou I,
Aravantinos G, Syrigos K and Stratigos A: Anti-PD1/PDL1 induced
psoriasis. Curr Probl Cancer. 41:407–412. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu S, Wu X, Shi Z, Huynh M, Jena PK, Sheng
L, Zhou Y, Han D, Wan YY and Hwang ST: Diet-induced obesity
exacerbates imiquimod-mediated psoriasiform dermatitis in anti-PD-1
antibody-treated mice: Implications for patients being treated with
checkpoint inhibitors for cancer. J Dermatol Sci. 97:194–200. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
https://www.mayoclinic.org/diseases-conditions/psoriasis/symptoms-causes/syc-20355840
|
|
15
|
Honma M, Kanai Y, Murotani K, Nomura T,
Ito K and Imafuku S: Itching and skin pain in real-life patients
with plaque psoriasis: Baseline analysis of the ProLOGUE study. J
Dermatol Sci. 105:189–191. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu S, Tu HP, Huang YC and Lan CCE: The
incidence of anxiety may not be correlated with severity of
psoriasis: A prospective pilot study. Med Hypotheses.
130:1092542019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang PW and Chu CY: Pembrolizumab-induced
linear psoriasis. Lung Cancer. 146:378–379. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dulos J, Carven GJ, van Boxtel SJ, Evers
S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P,
Punt CJ, et al: PD-1 blockade augments Th1 and Th17 and suppresses
Th2 responses in peripheral blood from patients with prostate and
advanced melanoma cancer. J Immunother. 35:169–178. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okiyama N and Tanaka R: Varied
immuno-related adverse events induced by immune-check point
inhibitors-nivolumab-associated psoriasiform dermatitis related
with increased serum level of interleukin-6. Nihon Rinsho Meneki
Gakkai Kaishi. 40:95–101. 2017.(In Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hara T, Mikita N, Ikeda T, Inaba Y,
Kunimoto K, Kaminaka C, Kanazawa N, Yamamoto Y and Jinnin M:
Psoriatic arthritis induced by anti-programmed death 1 antibody
pembrolizumab. J Dermatol. 46:e466–e467. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gadgeel S, Rodríguez-Abreu D, Speranza G,
Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell
SF, et al: Updated analysis from KEYNOTE-189: Pembrolizumab or
placebo plus pemetrexed and platinum for previously untreated
metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol.
38:1505–1517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suzuki M, Matsumoto S, Takeda Y and
Sugiyama H: Systemic psoriasiform dermatitis appeared after the
administration of pembrolizumab. Intern Med. 59:871–872. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Siciliano MA, Dastoli S, d'Apolito M,
Staropoli N, Tassone P, Tagliaferri P and Barbieri V:
Pembrolizumab-induced psoriasis in metastatic melanoma: Activity
and safety of apremilast, a case report. Front Oncol.
10:5794452020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fan Y, Xie W, Huang H, Wang Y, Li G, Geng
Y, Hao Y and Zhang Z: Association of immune related adverse events
with efficacy of immune checkpoint inhibitors and overall survival
in cancers: A systemic review and meta-analysis. Front Oncol.
11:6330322021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takama H, Shibata T, Ando Y, Yanagishita
T, Ohshima Y, Akiyama M and Watanabe D: Pembrolizumab-induced
psoriasis vulgaris successfully treated with apremilast. Eur J
Dermatol. 30:188–190. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Totonchy MB, Ezaldein HH, Ko CJ and Choi
JN: Inverse psoriasiform eruption during pembrolizumab therapy for
metastatic melanoma. JAMA Dermatol. 152:590–592. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bonigen J, Raynaud-Donzel C, Hureaux J,
Kramkimel N, Blom A, Jeudy G, Breton AL, Hubiche T, Bedane C,
Legoupil D, et al: Anti-PD1-induced psoriasis: A study of 21
patients. J Eur Acad Dermatol Venereol. 31:e254–e257. 2017.
View Article : Google Scholar : PubMed/NCBI
|
